The U.S. Food and Drug Administration found no suicide risk linked to GLP-1 weight loss drugs<\/p>\n<\/h3>\n
By I. Edwards HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Jan. 15, 2026 (HealthDay News) \u2014 Federal health regulators say popular weight loss drugs like Wegovy<\/a> and Zepbound<\/a> do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.<\/p>\n The U.S. Food and Drug Administration (FDA) said Tuesday that its latest safety review found no link between GLP-1 weight loss drugs and suicidal thoughts or behavior.<\/p>\n The request applies to Novo Nordisk\u2019s<\/a> Wegovy and its older drug Saxenda<\/a>, as well as Eli Lilly\u2019s<\/a> Zepbound.<\/p>\n GLP-1 drugs were first developed to treat type 2 diabetes<\/a>. They work by behaving like a hormone in the gut that helps people feel full, which can reduce appetite and lead to weight loss.<\/p>\n The FDA said it reviewed data from 91 placebo-controlled clinical trials involving 107,910 patients. Of those, 60,338 people took a GLP-1 drug, while 47,572 received a placebo.<\/p>\n The analysis found no higher risk of suicidal thoughts or behavior among people taking GLP-1 drugs compared to those who did not, according to the FDA.<\/p>\n It also found no increased risk for other mental health problems, including anxiety, depression, irritability or psychosis.<\/p>\n The agency had shared similar findings after a preliminary review in 2024, but said at that time that limited data meant a small risk could not be ruled out.<\/p>\n With more data available, the FDA said the evidence does not support a connection.<\/p>\n More information<\/strong><\/p>\n European Neuropsychopharmacology<\/em> has previously explored the association between suicidal thoughts and GLP-1 injections<\/a>.<\/p>\n